This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05907122
Recruitment Status : Recruiting
First Posted : June 18, 2023
Last Update Posted : April 12, 2024
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.

Condition or disease Intervention/treatment Phase
Melanoma Drug: ABP 206 Drug: FDA-licensed Nivolumab Drug: EU-authorized Nivolumab Phase 3

Detailed Description:

Eligible subjects will be randomized in a 1:1:1 ratio to receive either ABP 206, Food and Drug Administration (FDA)-licensed nivolumab, or European Union (EU)-authorized nivolumab.

The treatment period is in alignment with the maximum treatment duration for OPDIVO® (nivolumab, reference product) in the adjuvant setting for melanoma.

All subjects will be treated until recurrence of disease, unacceptable toxicity, or subject withdrawal of consent with a maximum of 1 year of treatment.

The total duration of study participation for each subject will be approximately 13 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 249 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: The study is double-blinded; therefore, the investigators, study personnel (with the exception of the data monitoring committee, authorized unblinded sponsor and contract research organization staff, and unblinded site pharmacy staff), and the study subjects will remain blinded to treatment allocation. ABP 206 and nivolumab will be coded and labeled to protect blinding.
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting
Actual Study Start Date : July 26, 2023
Estimated Primary Completion Date : July 30, 2025
Estimated Study Completion Date : July 30, 2025

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma
Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: ABP 206
Subjects will receive Dose A of ABP 206 via intravenous (IV) infusion.
Drug: ABP 206
ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.

Active Comparator: FDA-licensed Nivolumab
Subjects will receive Dose A of FDA-licensed Nivolumab via IV infusion.
Drug: FDA-licensed Nivolumab
FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
Other Name: OPDIVO®

Active Comparator: EU-authorized Nivolumab
Subjects will receive Dose A of EU-authorized Nivolumab via IV infusion.
Drug: EU-authorized Nivolumab
FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
Other Name: OPDIVO®




Primary Outcome Measures :
  1. Area Under the Serum Concentration-time Curve from Time Zero to 28 Days (AUC0-28d) [ Time Frame: Day 1 (Postdose) through Day 28 ]
    The PK similarity (AUC0-28d) of ABP 206 compared with nivolumab will be demonstrated in subjects with advanced melanoma in the adjuvant setting.

  2. Area Under the Serum Concentration-time Curve Over the Dosing Interval at Steady State (AUCtau_SS) [ Time Frame: Week 17 through Week 21 ]
    The PK similarity (AUCtau_ss) of ABP 206 compared with nivolumab will be demonstrated in subjects with advanced melanoma in the adjuvant setting.


Secondary Outcome Measures :
  1. Maximum Observed Serum Concentration Following the First Dose (Cmax_dose 1) [ Time Frame: Week 1 (Baseline) through Week 9, Week 17 to 29, Week 41, and Week 53 (End of Study) ]
    The comparison of PK (Cmax_dose 1) of ABP 206 with nivolumab will be determined in subjects with advanced melanoma in the adjuvant setting.

  2. Maximum Observed Serum Concentration at Steady State (Cmax_ss) [ Time Frame: Week 1 (Baseline) through Week 9, Week 17 to 29, Week 41, and Week 53 (End of Study) ]
    The comparison of PK (Cmax_ss) of ABP 206 with nivolumab will be determined in subjects with advanced melanoma in the adjuvant setting.

  3. Serum Concentrations at Predose (Ctrough) [ Time Frame: Week 1 (Baseline) through Week 9, Week 17 to 29, Week 41, and Week 53 (End of Study) ]
    The PK similarity (Ctrough) of ABP 206 compared with nivolumab determined in subjects with advanced melanoma in the adjuvant setting.

  4. Number of Subjects With Treatment-Emergent Serious Adverse Events [ Time Frame: Week 1 (First dose of study drug) through Week 53 (End of Study) ]
    The safety (treatment-emergent serious adverse events) of ABP 206 compared with nivolumab will be assessed in subjects with advanced melanoma in the adjuvant setting.

  5. Number of Subjects With Treatment-Emergent Adverse Events [ Time Frame: Week 1 (First dose of study drug) through Week 53 (End of Study) ]
    The safety (treatment-emergent adverse events) of ABP 206 compared with nivolumab will be assessed in subjects with advanced melanoma in the adjuvant setting.

  6. Number of Subjects With Treatment-emergent Adverse Events-of-interest [ Time Frame: Week 1 (First dose of study drug) through Week 53 (End of Study) ]
    The safety (treatment-emergent adverse events-of-interest) of ABP 206 compared with nivolumab will be assessed in subjects with advanced melanoma in adjuvant setting.

  7. Number of Subjects With Anti-drug Antibodies (ADAs) [ Time Frame: Predose on Week 1 (Baseline), Weeks 5, 9, 17, 21, 29, 41, and at Week 53 (End of Study) ]
    The immunogenicity of ABP 206 compared with nivolumab will be assessed in subjects with advanced melanoma in the adjuvant setting.

  8. Recurrence-free Survival (RFS) [ Time Frame: Randomization through 12 months (or until RFS criteria is met) ]
    The RFS is assessed to compare the efficacy of ABP 206 with nivolumab in subjects with advanced melanoma in the adjuvant setting. The RFS is defined as the time between the date of randomization and the date of first recurrence (local, regional, distant metastasis) or death (whatever the cause), or date of last visit/contact with disease assessments (for subjects who remain alive and whose disease has not recurred).

  9. Time to reach Cmax following the first dose (Tmax_dose 1) [ Time Frame: Week 1 (Baseline) through Week 9, Week 17 to 29, Week 41, and Week 53 (End of Study) ]
    The comparison of PK (Tmax_dose 1) of ABP 206 with nivolumab will be determined in subjects with advanced melanoma in the adjuvant setting.

  10. Time to reach Cmax at steady state (Tmax_ss) [ Time Frame: Week 1 (Baseline) through Week 9, Week 17 to 29, Week 41, and Week 53 (End of Study) ]
    The comparison of PK (Tmax_SS) of ABP 206 with nivolumab will be determined in subjects with advanced melanoma in the adjuvant setting.

  11. Serum Concentrations (Ctrough) [ Time Frame: At Week 5 (Pre-dose), and at Weeks 17 and 21 (Pre-dose) ]
    The comparison of PK (Ctrough) of ABP 206 with nivolumab will be determined in subjects with advanced melanoma in the adjuvant setting.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age
  • Completely removed melanoma by surgery performed within 12 weeks of randomization
  • Advanced Melanoma
  • Tumor tissue from the resected site of the disease must be available for biomarker analyses in order to be randomized
  • Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Exclusion Criteria:

  • Previous anti-cancer treatment
  • Known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug
  • Ocular or uveal melanoma or history of carcinomatosis meningitis
  • History of auto-immune disease
  • Subject has medical conditions requiring systemic immunosuppression with either corticosteroids or other immunosuppressive medications within 14 days of the first dose of the investigational product

Other protocol-defined inclusion/exclusion criteria apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05907122


Contacts
Layout table for location contacts
Contact: Amgen Call Center 1-800-772-6436 medinfo@amgen.com

Locations
Show Show 96 study locations
Sponsors and Collaborators
Amgen
Investigators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Layout table for additonal information
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT05907122    
Other Study ID Numbers: 20220083
First Posted: June 18, 2023    Key Record Dates
Last Update Posted: April 12, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data-sharing request for this study.
Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data-sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
URL: http://www.amgen.com/datasharing

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Amgen:
Pharmacokinetic similarity study
Adjuvant melanoma treatment
Advanced Melanoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Skin Neoplasms
Neoplasms by Site
Skin Diseases
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action